Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders

Dow Jones03-17

By Denny Jacob

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

The companies said they expect to file an investigational new drug application for their dual agonist GLP-1/glucagon peptide as a once-daily tablet with the Food and Drug Administration later this year.

Under the terms, Opko and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program's development costs.

Opko purchased around 3.7 million ordinary shares of Entera for a purchase price equal to $2.17 a share in connection with the agreement. Entera agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

March 17, 2025 08:57 ET (12:57 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520526318?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-17 20:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520526318","market":"nz","top_or_hot":-1,"title":"Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/OPK\">Opko Health</a> and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders. \n</p>\n<p>\n  The companies said they expect to file an investigational new drug application for their dual agonist GLP-1/glucagon peptide as a once-daily tablet with the Food and Drug Administration later this year. \n</p>\n<p>\n  Under the terms, Opko and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program's development costs. \n</p>\n<p>\n  Opko purchased around 3.7 million ordinary shares of Entera for a purchase price equal to $2.17 a share in connection with the agreement. Entera agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2025 08:57 ET (12:57 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-17 20:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/OPK\">Opko Health</a> and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders. \n</p>\n<p>\n  The companies said they expect to file an investigational new drug application for their dual agonist GLP-1/glucagon peptide as a once-daily tablet with the Food and Drug Administration later this year. \n</p>\n<p>\n  Under the terms, Opko and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program's development costs. \n</p>\n<p>\n  Opko purchased around 3.7 million ordinary shares of Entera for a purchase price equal to $2.17 a share in connection with the agreement. Entera agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2025 08:57 ET (12:57 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPK","symbol_name":"Opko Health","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2520526318","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520526318","pubTimestamp":1742216220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.The companies said they expect to file an investigational new drug application for their dual agonist GLP-1/glucagon peptide as a once-daily tablet with the Food and Drug Administration later this year.Under the terms, Opko and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program's development costs.Opko purchased around 3.7 million ordinary shares of Entera for a purchase price equal to $2.17 a share in connection with the agreement. Entera agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPK":"Opko Health","BK4196":"保健护理服务","ENTX":"Entera Bio Ltd.","BK4139":"生物科技"},"translate_title":"Opko Health与Entera Bio合作开发治疗肥胖、代谢和纤维化疾病的片剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTX":0.9,"OPK":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\nOpko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders. \n\n\n  The companies said they expect to file an investigational new drug application for their dual agonist GLP-1/glucagon peptide as a once-daily tablet with the Food and Drug Administration later this year. \n\n\n  Under the terms, Opko and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program's development costs. \n\n\n  Opko purchased around 3.7 million ordinary shares of Entera for a purchase price equal to $2.17 a share in connection with the agreement. Entera agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2025 08:57 ET (12:57 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520526318"}